Study wrapper · #1116
Weight Loss-Dependent Changes in Body Composition and Bone Health in People With Obesity and Type 1 Diabetes Treated With Liraglutide, Semaglutide, or Tirzepatide.
Editor's note
The signal worth noting here is what did not change: total bone mineral density held steady across a year of incretin-driven weight loss in a population with type 1 diabetes, a group already carrying elevated fracture risk. Lean mass did decline in proportion to total weight lost, which is consistent with the wider incretin literature and reinforces why resistance training and protein intake keep coming up in clinical discussion. This is an observational cohort of 70 people with no control arm, so read the results as reassuring rather than definitive.
Plain-language abstract
A real-world observational study followed 70 people with obesity and type 1 diabetes for 12 months on either a GLP-1 receptor agonist or a dual GIP/GLP-1 agent, using DEXA scans to track body composition and bone density. Body weight fell about 6.3%, HbA1c fell 0.48 points, and fat mass dropped more than lean mass. Total bone mineral content and density were unchanged. Those losing more than 10% of body weight gained the most metabolic benefit but also lost the most lean mass.